专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019147718A1 TREATMENT OF POST-BARIATRIC HYPOGLYCEMIA USING MINI-DOSE STABLE GLUCAGON 审中-公开
公开(公告)号：WO2019147718A1
公开(公告)日：2019-08-01
申请号：PCT/US2019/014815
申请日：2019-01-23
申请人： XERIS PHARMACEUTICALS, INC. , JOSELIN DIABETES CENTER
发明人： NEWSWANGER, Brett , PRESTRELSKI, Steven, J. , PATTI, Mary-Elizabeth
IPC分类号： A61K38/26 , A61K9/00 , A61K9/08 , A61K47/02 , A61K47/20 , A61K47/26 , A61P1/18 , A61P3/08 , A61P5/48
CPC分类号： A61P1/18 , A61K9/0019 , A61K9/0021 , A61K9/08 , A61K38/26 , A61K47/20 , A61K47/26 , A61P3/08 , A61P5/48
摘要： Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery. Current therapeutic options have suboptimal efficacy. Small doses of stable liquid glucagon can be used to treat or prevent post-bariatric hypoglycemia.

2. 发明申请

WO2019126753A1 TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES 审中-公开
公开(公告)号：WO2019126753A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/067294
申请日：2018-12-21
申请人： XERIS PHARMACEUTICALS, INC.
发明人： PRESTRELSKI, Steven , NEWSWANGER, Brett , CUMMINGS, Martin , RIDDELL, Mike
IPC分类号： A61K38/26 , A61P3/10
CPC分类号： A61P3/10 , A61K9/0014 , A61K9/0019 , A61K9/0021 , A61K9/0043 , A61K9/0073 , A61K9/06 , A61K9/08 , A61K9/10 , A61K9/107 , A61K38/26 , A61K47/02 , A61K47/10 , A61K47/20 , A61K47/26
摘要： Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise.

3. 发明申请

WO2014124151A1 METHODS FOR RAPIDLY TREATING SEVERE HYPOGLYCEMIA 审中-公开
标题翻译：快速治疗严重高血压的方法
公开(公告)号：WO2014124151A1
公开(公告)日：2014-08-14
申请号：PCT/US2014/015123
申请日：2014-02-06
申请人： XERIS PHARMACEUTICALS, INC.
发明人： PRESTRELKI, Steven, J. , NEWSWANGER, Brett
IPC分类号： A61K38/26 , A61K9/19 , A61P3/08
CPC分类号： A61K38/26 , A61K9/0019 , A61K9/19
摘要： Disclosed is a method for treating or preventing hypoglycemia in a patient comprising administering an effective amount of a composition comprising a glucagon peptide which has been dried in a buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the glucagon peptide in the buffer, and an aprotic polar solvent, wherein the dried glucagon peptide maintains the pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer when the dried glucagon peptide is reconstituted in the aprotic polar solvent, wherein the patient has been diagnosed as having a blood glucose level between 0 mg/dL and less than 60 mg/dL or has an indication of impending hypoglycemia based on a blood glucose monitoring device before administration of the composition, and wherein the patient's blood glucose level has been increased by at least 30 mg/dL within 1 to 30 minutes after administration of the composition.
摘要翻译：公开了一种用于治疗或预防患者中的低血糖的方法，包括给予有效量的包含已经在缓冲液中干燥的胰高血糖素肽的组合物，并且其中所述胰高血糖素肽具有约等于胰高血糖素肽和非质子极性溶剂，其中当干胰高血糖素肽在非质子极性溶剂中重构时，干燥的胰高血糖素肽保持pH记忆，其大约等于非挥发性缓冲液中胰高血糖素肽的pH值其中，所述患者被诊断为具有在0mg / dL至小于60mg / dL之间的血糖水平，或者在施用所述组合物之前具有基于血糖监测装置的即将发生的低血糖的指征，并且其中所述患者的血液葡萄糖水平在施用组合物后1至30分钟内已增加至少30mg / dL。

4. 发明申请

WO2019014658A1 METHODS FOR TREATING CONGENITAL HYPERINSULINISM 审中-公开
公开(公告)号：WO2019014658A1
公开(公告)日：2019-01-17
申请号：PCT/US2018/042197
申请日：2018-07-14
申请人： XERIS PHARMACEUTICALS, INC.
发明人： PRESTRELSKI, Steven , KINZELL, John , NEWSWANGER, Brett , THORNTON, Paul , STRANGE, Poul , CUMMINS, Marty
IPC分类号： A61K38/26 , A61P3/08 , A61M5/142
摘要： A method of treating congenital hyperinsulinism in a subject is disclosed. The method can include parenterally administering to the subject a first composition comprising a glucagon, a glucagon analogue, or a salt form of either thereof, and optionally administering to the subject a second composition comprising glucose, a glucose analogue, or a salt form of either thereof, wherein administration of the first composition sufficiently increases blood glucose level in the subject such that the second composition is not administered or the second composition is administered at a glucose infusion rate (GIR) of less than 8 mg/(kg*min).

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式